At a Glance
- Companies: Boehringer Ingelheim; Simcere Pharmaceutical Group
- Location: Ingelheim, Germany; Shanghai, China
- Deal value: Up to €1.058bn (~US$1.26bn); upfront undisclosed
- Focus area: TL1A/IL23p19 bispecific for inflammatory bowel disease
- Next steps: IND-enabling studies; Boehringer leads global development
What happened?
Boehringer Ingelheim and Simcere announced a license and collaboration agreement on 27 January 2026 for SIM0709, Simcere’s pre-clinical bispecific antibody targeting TL1A and IL23p19 in inflammatory bowel disease (IBD). Boehringer gains global rights excluding Greater China; Simcere eligible for upfront, milestones up to €1.058bn and royalties on ex-China sales.
Why does it matter?
IBD affects over 3 million globally, with current therapies failing to halt progression for many, leading to surgeries and hospitalisations. Dual-targeting TL1A/IL23p19 aims to surpass monotherapy efficacy ceilings, addressing high unmet need in ulcerative colitis and Crohn’s disease.
Who’s behind it?
Boehringer bolsters immunology pipeline via external innovation; Simcere leverages proprietary multi-specific platform—its second autoimmune out-licensing, totalling 5 deals worth ~$4.6bn potential.
How was it achieved?
SIM0709 engineered on Simcere’s platform showed superior preclinical efficacy vs. single agents; Boehringer’s IBD expertise accelerates clinic entry.
What’s next?
Boehringer advances IND-enabling work and phase 1 trials globally (ex-China); Simcere develops in Greater China.
What are people saying?
Carine Boustany, Boehringer: “Excited to join forces with Simcere to accelerate… a potential life changing option.” Gaobo Zhou, Simcere: “Partnering… positions the compound for rigorous global development.”